MedTrace Logo

Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study

NCT00396123 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2017-06-05

No results posted yet for this study

Summary

Humans have cells in their blood stream called endothelial progenitor cells or EPCs. These are thought to be important in keeping blood vessels healthy. People with chronic kidney disease (CKD) have low numbers of these cells. People with cardiovascular (heart and blood vessel) disease also have low numbers. Patients with CKD have more cardiovascular disease then any other group.Erythropoietin is a hormone made by the kidneys. It is essential for making red blood cells and also activates EPCs. It is low in people with kidney disease.

As part of your regular medical care for correcting your low red blood cell count, you will be receiving a medication that acts like erythropoietin. It is called darbepoetin.

The purpose of this study is to see if darbepoetin treatment affects EPC numbers and function.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Crystal A Gadegbeku, MD · University of Michigan/Internal Medicine/Nephrology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-07-25
Completion
2008-07-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396123 on ClinicalTrials.gov